Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Fulcrum Therapeutics ( (FULC) ) is now available.
On April 23, 2026, Fulcrum Therapeutics terminated its 2023 license agreement with CAMP4 Therapeutics covering rights to a Diamond-Blackfan anemia program, unwinding a deal that had provided Fulcrum with a worldwide exclusive license to certain small-molecule compounds and related intellectual property. The move narrows Fulcrum’s external pipeline exposure while leaving CAMP4 without the associated future milestones and royalties, as the undisclosed upfront payment remains the primary realized value of the collaboration.
Also on April 23, 2026, Fulcrum appointed sickle cell veteran Josh Lehrer to its board as an independent Class III director and Science & Technology Committee member, granting him stock options under the company’s standard non-employee director compensation plan. On the same date, Chief Financial Officer and treasurer Alan Musso notified the company of his plan to retire later in 2026, with Fulcrum launching a search for his successor and putting in place a transition and consulting arrangement through February 2027 to support continuity in financial leadership.
In a separate update dated April 27, 2026, the company reported first-quarter 2026 results, including an $18.9 million net loss on higher R&D and G&A expenses year over year, alongside a modest $19.0 million cash burn from operations. Fulcrum highlighted positive Phase 1b PIONEER data for pociredir in sickle cell disease, initiation of a long-term open-label study, acceptance of trial data for an upcoming scientific presentation, and a new collaboration with patient groups, developments that collectively reinforce its strategic emphasis on sickle cell disease and its capacity to fund clinical advancement well into the next phase of development.
The most recent analyst rating on (FULC) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.
Spark’s Take on FULC Stock
According to Spark, TipRanks’ AI Analyst, FULC is a Neutral.
The score is held down primarily by weak financial performance (persistent losses and renewed 2025 cash burn) and bearish technicals (price below key moving averages with negative momentum). These are partially offset by a more positive earnings-call backdrop driven by encouraging early clinical signals and a defined regulatory path, while valuation support is limited due to a negative P/E and no dividend yield.
To see Spark’s full report on FULC stock, click here.
More about Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for rare hematological disorders, with a lead program, pociredir, designed to increase fetal hemoglobin for the treatment of sickle cell disease. The company leverages proprietary gene expression modulation technology to identify drug targets that address the root causes of genetically defined diseases and reported cash, cash equivalents, and marketable securities of $333.3 million as of March 31, 2026, providing a cash runway into 2029.
Average Trading Volume: 1,032,505
Technical Sentiment Signal: Hold
Current Market Cap: $522.1M
Find detailed analytics on FULC stock on TipRanks’ Stock Analysis page.